Market capitalization | GBP179.87b |
Enterprise Value | GBP199.61b |
P/E (TTM) P/E ratio | 32.59 |
EV/FCF (TTM) EV/FCF | 24.81 |
EV/Sales (TTM) EV/Sales | 4.72 |
P/S ratio (TTM) P/S ratio | 4.25 |
P/B ratio (TTM) P/B ratio | 5.92 |
Dividend yield | 2.48% |
Last dividend (FY24) | GBP2.88 |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
33 Analysts have issued a AstraZeneca forecast:
33 Analysts have issued a AstraZeneca forecast:
Dec '24 |
+/-
%
|
||
Revenue | 42,307 42,307 |
15%
15%
|
|
Gross Profit | 30,568 30,568 |
14%
14%
|
|
EBITDA | 13,767 13,767 |
33%
33%
|
EBIT (Operating Income) EBIT | 8,542 8,542 |
43%
43%
|
Net Profit | 5,515 5,515 |
15%
15%
|
In millions GBP.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Head office | United Kingdom |
CEO | Pascal Soriot |
Founded | 1992 |
Website | www.astrazeneca.co.uk |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.